163 related articles for article (PubMed ID: 35411430)
1. FBXO32 targets PHPT1 for ubiquitination to regulate the growth of EGFR mutant lung cancer.
Zhang N; Liao Y; Lv W; Zhu S; Qiu Y; Chen N; Xiao M; Zhang H
Cell Oncol (Dordr); 2022 Apr; 45(2):293-307. PubMed ID: 35411430
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance.
Ray P; Raghunathan K; Ahsan A; Allam US; Shukla S; Basrur V; Veatch S; Lawrence TS; Nyati MK; Ray D
J Biol Chem; 2020 Sep; 295(36):12661-12673. PubMed ID: 32669362
[TBL] [Abstract][Full Text] [Related]
3. FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation.
Zhou H; Liu Y; Zhu R; Ding F; Wan Y; Li Y; Liu Z
Oncogene; 2017 Jun; 36(23):3312-3321. PubMed ID: 28068319
[TBL] [Abstract][Full Text] [Related]
4. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
[TBL] [Abstract][Full Text] [Related]
5. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Zhang H; Han B; Lu H; Zhao Y; Chen X; Meng Q; Cao M; Cai L; Hu J
Cancer Lett; 2018 Oct; 433():186-198. PubMed ID: 29981430
[TBL] [Abstract][Full Text] [Related]
6. DNMT1-mediated regulating on FBXO32 promotes the progression of glioma cells through the regulation of SKP1 activity.
Quan J; Ma C
Environ Toxicol; 2024 Feb; 39(2):783-793. PubMed ID: 37782699
[TBL] [Abstract][Full Text] [Related]
7. NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.
Wang X; Yin H; Zhang H; Hu J; Lu H; Li C; Cao M; Yan S; Cai L
Cell Death Dis; 2018 Apr; 9(4):418. PubMed ID: 29549343
[TBL] [Abstract][Full Text] [Related]
8. FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.
Mei Z; Zhang D; Hu B; Wang J; Shen X; Xiao W
J Biol Chem; 2015 Jun; 290(26):16202-14. PubMed ID: 25944903
[TBL] [Abstract][Full Text] [Related]
9. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Segura-Carretero A; Joven J; Martin-Castillo B; Barrajón-Catalán E; Micol V; Bosch-Barrera J; Menendez JA
Cell Cycle; 2013 Nov; 12(21):3390-404. PubMed ID: 24047698
[TBL] [Abstract][Full Text] [Related]
10. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.
Gong Y; Somwar R; Politi K; Balak M; Chmielecki J; Jiang X; Pao W
PLoS Med; 2007 Oct; 4(10):e294. PubMed ID: 17927446
[TBL] [Abstract][Full Text] [Related]
11. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
[TBL] [Abstract][Full Text] [Related]
12. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Bivona TG; Hieronymus H; Parker J; Chang K; Taron M; Rosell R; Moonsamy P; Dahlman K; Miller VA; Costa C; Hannon G; Sawyers CL
Nature; 2011 Mar; 471(7339):523-6. PubMed ID: 21430781
[TBL] [Abstract][Full Text] [Related]
13. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers.
Chen C; Liu WR; Zhang B; Zhang LM; Li CG; Liu C; Zhang H; Huo YS; Ma YC; Tian PF; Qi Q; Li JJ; Tang Z; Zhang ZF; Giaccone G; Yue DS; Wang CL
Cancer Lett; 2020 Aug; 486():58-70. PubMed ID: 32439420
[TBL] [Abstract][Full Text] [Related]
14. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
16. The atypical ubiquitin ligase RNF31 stabilizes c-Myc via epigenetic inactivation of FBXO32 and promotes cancer development.
Chen Z; Ren D; Lv J; Xu Y; Xie M; He X; Shi W; Qian Q; Jing A; Ma X; Qin J; Ding Y; Geng T; Ma J; Liu W; Liu S; Ji J
Cell Signal; 2023 Jul; 107():110677. PubMed ID: 37028779
[TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
18. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
[TBL] [Abstract][Full Text] [Related]
19. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
